Pharmacological and Parenteral Therapies.

Which of the following safety protocols is most important when caring for a patient who is receiving intravenous potassium?

The nurse is caring for a patient receiving a blood transfusion. The patient develops chills, fever, and back pain during the infusion. What is the nurse’s priority action?

A nurse is administering a blood transfusion. The patient begins to experience chills, fever, and itching. What is the nurse’s immediate action?

The nurse is caring for a patient with a central venous catheter (CVC) who develops a fever and swelling at the catheter insertion site. What should the nurse do first?

A patient with asthma is prescribed a bronchodilator. Which of the following is the most common side effect of this medication?

A nurse is caring for a pat ient who is receiving total parenteral nutrition (TPN). The nurse should monitor which of the following to evaluate the patient's tolerance to the TPN solution?

A nurse is administering a diuretic to a patient with heart failure. Which of the following laboratory values should the nurse monitor close ly?

The nurse is preparing to administer a blood transfusion to a p atient. Which of the following actions is necessary to ensure patient safety?

A nurse is caring for a patient receiving heparin therapy. The nurse should monitor for which of the following complications?

A patient with a history of myocardial infarction (MI) is prescribed a beta -blocker. Which of the following assessments should the nurse prioritize for this patient?

The nurse is c aring for a patient receiving an intravenous (IV) infusion of potassium chloride. The nurse observes that the IV site is red, swollen, and warm to the touch. What is the nurse’s first action?

A patient is receiving chemotherapy and complains of n ausea and vomiting. What is the nurse’s priority intervention?

A patient with chronic obstructive pulmonary disease (COPD) is being treated with a corticosteroid inhaler. Which of the following instructions should the nurse provide regarding the use of the inhaler?

A patient is receiving IV potassium chloride for hypokalemia. The nurse notices that the infusion site is swollen and warm to the touch. What should the nurse do first?

A nurse is caring for a patient with asthma who is prescribed a corticosteroid inhaler. The nurse notices that t he patient’s mucous membranes are dry and irritated. Which of the following is the best action to take?

The nurse is administering a blood transfusion to a patient with anemia. Which of the following should the nurse monitor throughout the transfusion process?

The nurse is caring for a patient with heart failure who is prescribed a diuretic. Which laboratory value should the nurse monitor to assess for potential complications?

A patient with heart failure is prescribed digoxin. The nurse should monitor for signs of digoxin toxicity, including:

A patient with liver disease is prescribed a diuretic to manage fluid retention. Which electrolyte imbalance is the nurse most concerned about in this patient?

A nurse is caring for a patient with type 2 diabetes who has been prescribed insulin. The patient is experiencing hypoglycemia. Which of the following should the nurse administer to the patient?

A nurse is preparing to administer a blood transfusion. Which of the following actions is essential before starting the transfusion?

A nurse is educating a patient on the proper use of a dry powder inhaler (DPI) for asthma. Which instruction should the nurse provide?

A patient with a history of asthma is prescribed a corticosteroid inhaler. The nurse should instruct the patient to:

A nurse is caring for a patient who is post -operative and receiving an opioid for pain management. The nurse should be concerned about which of the following symptoms?

A nurse is caring for a patient with deep vein thrombosis (DVT). The nurse is preparing to administer heparin. What should the nurse assess before administration?

A pregnant client is receiving magnesium sulfate for the management of preeclampsia. A nurse determines the client is experiencing toxicity from the medication if which of the following is noted on assessment?

The antagonist for magnesium sulfate should be readily available to any client receiving IV magnesium. Which of the following drugs is the antidote for magnesium toxicity?

Some central venous access devices (CVAD) have more tha n one lumen. These multi lumen catheters: a. Have an increased risk of infiltration. b. Only work a short while because the small bore clots off. c. Are beneficial to patient care but are prohibitively expensive. d. Allow different medications or solutions to be administered simultaneously.

The chemotherapeutic DNA alkylating agents such as nitrogen mustards are effectiv e because they: 139 a. Cross -link DNA strands with covalent bonds between alkyl groups on the drug and guanine bases on DNA. b. Have few, if any, side effects. c. Are used to treat multiple types of cancer. d. Are cell cycle -specific agents.

Currently, there is no way to prevent myelosuppression. However, there are medications available to elicit a more rapid b one marrow recovery. An example is: a. Epoet in alfa (Epogen, Procrit). b. Glucagon. c. Fenofibrate (Tricor). d. Lamotrigine (Lamictal).

Superficial bladder cancer can be treated by direct instillation of the antineoplastic antibiotic agent mitomycin (Mutamycin). This process is termed: a. Intraventricular administration. b. Intravesical administration. c. Intravascular administration. d. Intrathecal administration.

Medications bound to protein have the following effect: a. Enhancement of drug availability. b. Rapid distribution of the drug to receptor sites. c. The more drug bound to pro tein, the less available for desired effect. d. Increased metabolism of the drug by the liver.

An adult patient has been taking a drug (Drug A) that is highly metabolized by the cytochrome p -450 system. He has been on this medication for 6 months. At this tim e, he is started on a second medication (Drug B) that is an inducer of the cytochrome p - 450 system. You should monitor this patient for: 141 a. Increased therapeutic effects of Drug A. b. Increased adverse effects of Drug B. c. Decreased therapeutic effects of Drug A. d. Decreased therapeutic effects of Drug B.